Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-342.63%
operating margin TTM
-348.01%
revenue TTM
38.67 Million
revenue per share TTM
0.72$
valuation ratios | |
|---|---|
| pe ratio | -4.54 |
| peg ratio | 0.26 |
| price to book ratio | 5.52 |
| price to sales ratio | 17.36 |
| enterprise value multiple | -5.75 |
| price fair value | 5.52 |
profitability ratios | |
|---|---|
| gross profit margin | 51.88% |
| operating profit margin | -348.01% |
| pretax profit margin | -342.63% |
| net profit margin | -342.63% |
| return on assets | -44.34% |
| return on equity | -159.54% |
| return on capital employed | -54.92% |
liquidity ratio | |
|---|---|
| current ratio | 2.88 |
| quick ratio | 2.88 |
| cash ratio | 1.57 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 114.72 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 114.72 |
| receivables turnover | 3.18 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.31 |
| debt equity ratio | 0.86 |
| long term debt to capitalization | 0.46 |
| total debt to capitalization | 0.46 |
| interest coverage | -17.73 |
| cash flow to debt ratio | -1.16 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.46 |
| cash per share | 1.87 |
| operating cash flow per share | -1.46 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -1.16 |
| short term coverage ratios | -128.84 |
| capital expenditure coverage ratio | -966.29 |
Frequently Asked Questions
When was the last time Zevra Therapeutics, Inc. (NASDAQ:ZVRA) reported earnings?
Zevra Therapeutics, Inc. (ZVRA) published its most recent earnings results on 13-11-2024.
What is Zevra Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Zevra Therapeutics, Inc. (NASDAQ:ZVRA)'s trailing twelve months ROE is -159.54%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Zevra Therapeutics, Inc. (ZVRA) currently has a ROA of -44.34%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ZVRA's net profit margin stand at?
ZVRA reported a profit margin of -342.63% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ZVRA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.88 in the most recent quarter. The quick ratio stood at 2.88, with a Debt/Eq ratio of 0.86.